Scientists have created a drug that independently destroys fat cells
In clinical trials of the experimental drug CBL-514 was able to reduce the amount of visceral fat in the abdomen by an average of 12% in four weeks.

In clinical trials of the experimental drug CBL-514 was able to reduce the amount of visceral fat in the abdomen by an average of 12% in four weeks. The drug destroys fat cells without affecting appetite, reports Hi-Tech Mail with reference to the New York Post.
The drug is injected directly into the abdomen. It blocks the protective mechanism of fat cells, after which they die. Unlike GLP-1-based drugs, including Ozempic, CBL-514 acts directly at the injection site.
GLP-1 (glucagon-like peptide-1) is an intestinal hormone that regulates blood sugar levels and affects hunger.
The drug affects both subcutaneous and visceral fat, which surrounds the internal organs. Excess visceral fat increases the risk of diabetes, heart attack and stroke.
Visceral fat is fat that accumulates in the abdomen and surrounds internal organs, including the liver and intestines.
In the second phase of the clinical trial, participants were given injections every three weeks. After eight weeks, the amount of visceral fat remained 10.45% below baseline.
The developers suggest that the effect of the drug can persist for a long time, since the destroyed fat cells may not recover. So far, studies have only been done on rats. Whether the effect will persist in humans, further tests will show.
Among the identified side effects were pain, swelling and redness at the injection site, which went away on their own. Serious adverse events during the study were not recorded.
The drug has entered the third phase of clinical trials, after which developers will be able to apply for approval by the US Food and Drug Administration (FDA). Professor Timothy Garvey of the University of Alabama called this approach a new direction in the treatment of obesity.
Earlier, specialists of the Federal Research Center for Nutrition and Biotechnology developed bread that promotes weight loss. The product is intended for inclusion in the diet of people with overweight, obesity and metabolic syndrome.



